Impact of Vitamin D Supplementation on COVID-19 Vaccine Response and IgG Antibodies in Deficient Women. (CoVıD-19)
COVID-19 Pandemic, D Vitamin Deficiency, Antibody Hypersensitivity
About this trial
This is an interventional supportive care trial for COVID-19 Pandemic focused on measuring COVID-19 Vaccine, Antibody, IgG, D vitamin, Nutrition
Eligibility Criteria
Inclusion Criteria:
- The study consisted of young volunteer women who completed 2 doses of COVID-19 vaccines, did not receive the 3rd dose, and spent an average of 65 days over the 2nd dose. Participants were included in the study when IgM value was negative, IgG value was positive, they were not older than 25 years, and serum 25-Hydroxy (25(OH)) vitamin D was below 30 ng/mL.
Exclusion Criteria:
- In addition, individuals participating in the research who were pregnant, had physician-diagnosed cardiovascular diseases, had kidney or liver failure, and had the chronic obstructive pulmonary disease were not included in the study.
Sites / Locations
- Avrasya University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Participants using vitamin D supplements
Participants not using vitamin D supplements
Participants in the experimental group were given 150,000 IU (10 ml) of vitamin D3 supplementation, and it was used regularly for 2 months. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.
No supplement was given to the control group. From the first measurement, 2 more measurements were taken, 28 days apart, and a total of 3 measurements were taken from the participants.